AF Association News & Events
AF ASSOCIATION NAMES WINNERS OF PRESTIGIOUS UK HEALTHCARE PIONEER AWARDS
Heart Rhythm Congress, ICC, Birmingham: Trudie Lobban, Founder and CEO, AF Association announced this year’s winners of the AF Association “UK Healthcare Pioneers 2018 – Showcasing Best Practice in AF” at the Arrhythmia Alliance Awards Ceremony.
AF CAUSES ONE THIRD OF ALL STROKES – THESE CAN BE PREVENTED, THIS SCANDAL CANNOT BE ALLOWED TO CONTINUE
Many of the world’s leading authorities on the management and treatment of atrial fibrillation (AF) met at the Heart Rhythm Congress to present the case for perfecting the care of AF patients: Detect AF by a simple pulse check; perfect against AF-related stroke using anticoagulation therapy, not aspirin; and correct the irregular heart rhythm with access to appropriate treatment.
Wearable Technology: Safeguards will help boost sales
This month Apple claimed that its much-feted, but reportedly under-selling, Apple Watch had saved lives. In one case a 62-year-old builder felt terrible after lunch. His watch had revealed an abnormally high pulse and he called an ambulance. Doctors were said to have told him that he might have died if he had gone straight home. This is a good news story, but medical specialists fear that it may create a misleading impression about the accuracy of personal pulse checkers in hand-held monitors and smartphones.
INTERNATIONAL HEART RHYTHM CONGRESS CALLS FOR URGENT ACTION TO PREVENT THOUSANDS OF UNNECESSARY DEATHS FROM ARRHYTHMIAS..
Over 3,000 heart rhythm specialists and healthcare professionals from around the world are arriving in Birmingham for the annual Heart Rhythm Congress (HRC), starting on Sunday (1-4 October), the UK’s largest educational congress devoted solely to arrhythmias (heart rhythm disorders).
PATIENT DIES AFTER BEING DENIED ACCESS TO LIFE-SAVING TREATMENT DUE TO LACK OF NHS FUNDING
Arrhythmia Alliance is calling on NHS England to reconsider its ‘Commissioning through Evaluation’ (CtE) process, following the death of a high risk atrial fibrillation (AF) patient from a bleed to the brain after being refused a potentially life-saving treatment. The evaluation process of left atrial appendage occlusion (LAAO), a treatment approved by the FDA and used across Europe, has meant hundreds of patients being denied access to this treatment with no guarantee when the evaluation will be completed to allow access.
ARRHYTHMIA ALLIANCE WELCOMES NHS CALL TO PROVIDE TESTS TO IDENTIFY PEOPLE WITH UNDIAGNOSED HEART RHYTHM DISORDERS
Local health authorities do not mandate or commission manual pulse rhythm checks recommended as part of NHS health check service
LOCAL HEART RHYTHM CHARITY PARTNERS WITH FBI
Wednesday 2 August: Chipping Norton, UK: Today at the annual FBI National Academy Associates conference held in Washington DC, USA, Trudie Lobban MBE, Founder and Trustee, Arrhythmia Alliance is calling on all delegates in attendance and to Police Chiefs across the United States to place an automated external defibrillator (AED) in every police vehicle to help save lives from sudden cardiac death – the number one killer in the USA.
High Risk Patients Denied Access to Life-saving Treatment
Arrhythmia Alliance is concerned about high risk arrhythmia (heart rhythm disorder) patients who are being secretly denied access to life-saving treatment due to an 'indefinite' NHS England 'evaluation process'.
Interview with Trudie Lobban MBE, Founder & Trustee of Arrhythmia Alliance
Arrhythmia Alliance is a coalition of charities, patient groups, patients, carers, healthcare professionals, policy-makers, politicians, allied professionals and all those involved in the care of or affected by cardiac arrhythmias. Arrhythmia Alliance works in collaboration to improve diagnosis, treatment and quality of life for all those suffering with arrhythmias.
Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE)
Atrial fibrillation (AF) is the most common cardiac arrhythmia, occurring in 1–2% of the general population. Its prevalence varies between continents and ethnicity, but the estimated number of patients with AF worldwide might be between 30 and 100 million.1 This prevalence is expected to increase significantly in the next 30–50 years due to an ageing population, and increasing risk factors to develop AF, including arterial hypertension and diabetes.2–5 In all populations studied, both prevalence and incidence are higher in men than in women and increase with age.6